Compare RPM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPM | ROIV |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8B | 14.1B |
| IPO Year | N/A | N/A |
| Metric | RPM | ROIV |
|---|---|---|
| Price | $107.31 | $20.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $128.50 | $21.19 |
| AVG Volume (30 Days) | 821.2K | ★ 7.9M |
| Earning Date | 01-06-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 12.29 | N/A |
| EPS | ★ 5.36 | N/A |
| Revenue | ★ $7,517,598,000.00 | $20,329,000.00 |
| Revenue This Year | $6.95 | N/A |
| Revenue Next Year | $3.37 | $320.50 |
| P/E Ratio | $20.03 | ★ N/A |
| Revenue Growth | ★ 3.09 | N/A |
| 52 Week Low | $95.28 | $8.73 |
| 52 Week High | $140.41 | $21.35 |
| Indicator | RPM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 68.70 |
| Support Level | $101.75 | $19.99 |
| Resistance Level | $108.07 | $20.99 |
| Average True Range (ATR) | 2.03 | 0.68 |
| MACD | 0.54 | -0.14 |
| Stochastic Oscillator | 78.72 | 71.47 |
RPM International Inc manufactures and sells a variety of paints, coatings, and adhesives. The firm organizes itself into four segments based on product type. The construction products group sells coatings, roofing, insulation, and other products to distributors, contractors, and end consumers globally. The performance coatings group produces coatings that are used in construction and industrial applications like floorings and corrosion control. The consumer group sells paint, finishes, and similar products to individual consumers through hardware and craft stores. The specialty products group sells a line of products ranging from niche applications of the other groups to marine finishes, to edible food colorings. The majority of revenue is from the construction products and North America.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.